• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Astrazen Share Price

    Astrazeneca Pharma India Share PriceAstraZeneca Pharma India

    Mid Cap 5.3k Result
    ₹4,832.65
    32.1 (0.67%)
    As on 06 December, 2023 | 04:36 BSE: 506820 NSE: ASTRAZENISIN: INE203A01020

    Astrazeneca Pharma India Performance

    Day Range

    • Low 4,726.85
    • High 4,875.00
    ₹ 4,832.65

    52 Week Range

    • Low 3,098.00
    • High 4,996.90
    ₹ 4,832.65
    • Open Price4,800.00
    • Previous Close4,800.55
    • Volume9296

    Start SIP in AstraZeneca Pharma India

    Start SIP

    Astrazeneca Pharma India Share Price

    • Over 1 Month 3.58%
    • Over 3 Month 11.58%
    • Over 6 Month 39.93%
    • Over 1 Year 46.23%

    Astrazeneca Pharma India Key Statistics

    P/E Ratio 79.1
    PEG Ratio 1.2
    Market Cap Cr 12,082
    Price to Book Ratio 20.5
    EPS 50.5
    Dividend 0.3
    Relative Strength Index 63.4
    Money Flow Index 68.96
    MACD Signal 27.32
    Average True Range 108.49

    Astrazeneca Pharma India Investment Rating

    • Master Rating:

    • Astrazeneca Pharma India has an operating revenue of Rs. 1,141.05 Cr. on a trailing 12-month basis. An annual revenue growth of 25% is outstanding, Pre-tax margin of 13% is healthy, ROE of 16% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 24% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 93 which is a GREAT score indicating consistency in earnings, a RS Rating of 65 which is FAIR indicating the recent price performance, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 76 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    AstraZeneca Pharma India Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 311295285250236232232
    Operating Expenses Qtr Cr 258228225213195204194
    Operating Profit Qtr Cr 53676037412838
    Depreciation Qtr Cr 4444354
    Interest Qtr Cr 1000000
    Tax Qtr Cr 21186101279
    Net Profit Qtr Cr 52541729332028
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 1,029820
    Operating Expenses Annual Cr 838719
    Operating Profit Annual in Cr 16586
    Depreciation Cr 1617
    Interest Annual Cr 11
    Tax Annual Cr 3521
    Net Profit Annual Cr 9962
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 58101
    Cash from Investing Activity Annual Cr 185
    Cash from Financing Annual Activity Cr -24-9
    Net Cash Flow Annual Cr 5296
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 589511
    Fixed Assets Annual Cr 7077
    Total Non Current Assets Annual Cr 149151
    Total Current Assets Annual Cr 835706
    Total Assets Annual Cr 985857
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 235205
    ROE Annual % 1712
    ROCE Annual % 2916
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1913
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr
    Operating Expenses Qtr Cr
    Operating Profit Qtr Cr
    Depreciation Qtr Cr
    Interest Qtr Cr
    Tax Qtr Cr
    Net Profit Qtr Cr
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr
    Operating Expenses Annual Cr
    Operating Profit Annual in Cr
    Depreciation Cr
    Interest Annual Cr
    Tax Annual Cr
    Net Profit Annual Cr
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr
    Cash from Investing Activity Annual Cr
    Cash from Financing Annual Activity Cr
    Net Cash Flow Annual Cr
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr
    Fixed Assets Annual Cr
    Total Non Current Assets Annual Cr
    Total Current Assets Annual Cr
    Total Assets Annual Cr
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs
    ROE Annual %
    ROCE Annual %
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin %
    Invest in Astrazeneca Pharma India

    Astrazeneca Pharma India Technicals

    EMA & SMA

    Current Price
    ₹4,832.65
    32.1 (0.67%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹4,718.38
    • 50 Day
    • ₹4,614.76
    • 100 Day
    • ₹4,385.47
    • 200 Day
    • ₹4,044.44
    • 20 Day
    • ₹4,713.43
    • 50 Day
    • ₹4,662.81
    • 100 Day
    • ₹4,365.14
    • 200 Day
    • ₹3,871.74

    Astrazeneca Pharma India Resistance and Support

    PIVOT
    ₹4,811.5
    Resistance
    First Resistance 4,896.15
    Second Resistance 4,959.65
    Third Resistance 5,044.30
    RSI 63.40
    MFI 68.96
    MACD Single Line 27.32
    MACD 38.66
    Support
    First Resistance 4,748.00
    Second Resistance 4,663.35
    Third Resistance 4,599.85

    Astrazeneca Pharma India Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 9,732 547,717 56.28
    Week 9,533 578,641 60.7
    1 Month 11,212 529,213 47.2
    6 Month 17,061 868,388 50.9

    Astrazeneca Pharma India Result Highlights

    AstraZeneca Pharma India Synopsis

    NSE-Medical-Diversified

    Astrazeneca Pharma I is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1002.97 Cr. and Equity Capital is Rs. 5.00 Cr. for the Year ended 31/03/2023. AstraZeneca Pharma India Ltd. is a Public Limited Listed company incorporated on 11/07/1979 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L24231KA1979PLC003563 and registration number is 003563.
    Market Cap 12,082
    Sales 1,141
    Shares in Float 0.63
    No of funds 92
    Yield 0.33
    Book Value 20.52
    U/D Vol ratio 1.1
    LTDebt / Equity
    Alpha 0.12
    Beta 0.43

    AstraZeneca Pharma India

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 75%75%75%75%
    Mutual Funds 2.42%1.76%1.22%1.22%
    Foreign Portfolio Investors 2.69%2.68%2.7%2.61%
    Financial Institutions/ Banks
    Individual Investors 17.44%18.12%18.46%18.56%
    Others 2.45%2.44%2.62%2.61%

    AstraZeneca Pharma India Management

    Name Designation
    Mr. Narayan K Seshadri Chairman & Ind.Director
    Mr. Sanjeev Kumar Panchal Executive Director
    Mr. Rajesh Marwaha Executive Director
    Mr. Ankush Nandra Non Executive Director
    Ms. Shilpa Shidhar Divekar Independent Director
    Ms. Weiying Sarah Wang Non Executive Director
    Ms. Revathy Ashok Independent Director

    Astrazeneca Pharma India Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Astrazeneca Pharma India Corporate Action

    Date Purpose Remarks
    2023-11-09 Quarterly Results
    2023-08-14 Quarterly Results
    2023-05-30 Audited Results & Dividend
    2023-02-10 Quarterly Results
    2022-11-11 Quarterly Results
    Date Purpose Remarks
    2023-07-14 FINAL Rs.16.00 per share(800%)Dividend
    2022-07-08 FINAL Rs.8.00 per share(400%)Final Dividend
    2021-08-20 INTERIM Rs.2.00 per share(100%)Interim Dividend

    AstraZeneca Pharma India MF Shareholding

    Name Amount(cr)
    Nippon India Small Cap Fund - Growth 37,319
    ICICI Prudential Innovation Fund Regular Growth 2,383
    Motilal Oswal Nifty Microcap 250 Index Fund Regular Growth 461
    Quant Healthcare Fund Regular Growth 162
    ICICI Prudential S&P BSE 500 ETF 128

    AstraZeneca Pharma India FAQs

    What is Share Price of AstraZeneca Pharma India ?

    AstraZeneca Pharma India share price is ₹4,832 As on 06 December, 2023 | 04:22

    What is the Market Cap of AstraZeneca Pharma India ?

    The Market Cap of AstraZeneca Pharma India is ₹12081.6 Cr As on 06 December, 2023 | 04:22

    What is the P/E ratio of AstraZeneca Pharma India ?

    The P/E ratio of AstraZeneca Pharma India is 79.1 As on 06 December, 2023 | 04:22

    What is the PB ratio of AstraZeneca Pharma India ?

    The PB ratio of AstraZeneca Pharma India is 20.5 As on 06 December, 2023 | 04:22

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.